
	{
		"patientInfo": {
			"id": 1210000006244,
			"protocolNo": 1200000003296,
			"patProtocolname": "Enzalutamide in Visceral Mets",
			"shortName": "PrPEnz",
			"diagnosisNo": null,
			"diagnosisVal": "Prostate- Castration-Recurrent\nFirst-Line Therapy WITH Visceral Metastases",
			"toxicity": null,
			"cycleDays": 30,
			"totalCycle": 7,
			"comments": "160mg (four 40mg capsules) orally daily with or without food; prednisone can be given concurrently but is not required.",
			"note": null,
			"referenceFrom": "Xtandi [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; 2016/ Beer TM, Armstrong AJ, Rathkopf DE, et al; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433",
			"finalizeFlag": 1,
			"startingDate": 1620530192000,
			"status": null,
			"doctorNo": 3248,
			"regNo": 1170000100717,
			"patientName": "MS. NUSRAT JAHAN",
			"genderData": "Female",
			"dob": null,
			"age": "32Y 4M 24D",
			"phoneMobile": "01710022260",
			"hospitalId": "11607648500",
			"consultationNo": null,
			"consultationId": null,
			"activeStatus": 1,
			"doctorName": "Dr. Md. Arifur Rahman",
			"doctorDegree": "MBBS",
			"userName": "Fajle",
			"scheduleNote": null,
			"requestDate": null,
			"patOtherDataDtoList": [
				{
					"id": 1210000002096,
					"parentNo": 1210000006244,
					"parentType": 16,
					"otherDataType": 18,
					"otherData": "Height",
					"findings": "5",
					"unit": "cm",
					"referenceId": 1200000001560,
					"inReportSerial": 1,
					"activeStat": 1,
					"showInReport": 1
				},
				{
					"id": 1210000002097,
					"parentNo": 1210000006244,
					"parentType": 16,
					"otherDataType": 18,
					"otherData": "Weight",
					"findings": "67",
					"unit": "kg",
					"referenceId": 1200000001563,
					"inReportSerial": 2,
					"activeStat": 1,
					"showInReport": 1
				},
				{
					"id": 1210000002098,
					"parentNo": 1210000006244,
					"parentType": 16,
					"otherDataType": 18,
					"otherData": "BSA",
					"findings": "0.31",
					"unit": null,
					"referenceId": 1200000001564,
					"inReportSerial": 3,
					"activeStat": 1,
					"showInReport": 1
				}
			],
			"oncoPatDrugReqDtlDtoList": null,
			"mstatusdata": "Single"
		},
		"oncoPatProtocolList": [
			{
				"id": 1210000006240,
				"protocolNo": 1200000003277,
				"patProtocolName": "Neoadjuvant/Adjuvant DOCEtaxel, CARBOplatin, and Trastuzumab",
				"shortName": "BrAjTCarbHq3w",
				"diagnosisNo": null,
				"diagnosisVal": "Breast- Invasive HER2-Positive Disease, Preferred Regimens",
				"toxicity": "Docetaxel- Alopecia++ GI Toxicity++ Neurotoxicity + Meyolotoxicity + Skin Changes+ Allergic Reactions+\nCarboplatin- GI Toxicity+ Neurotoxicity ++ Urological Toxicity + Meyolotoxicity +",
				"cycleDays": 21,
				"totalCycle": 5,
				"comments": ">Use non-DEHP tubing with 0.22 micron or smaller in-line filter.\n>Evaluate left ventricular ejection fraction (LVEF) before and during treatment. Although the optimal frequency of LVEF assessment during adjuvant trastuzumab therapy is not known, the FDA recommends LVEF measurements every 3 months during treatment",
				"note": null,
				"referenceFrom": "Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14): 1273–1283",
				"finalizeFlag": 1,
				"startingDate": 1620214318000,
				"status": null,
				"doctorNo": 3248,
				"regNo": 1170000100717,
				"hospitalId": "11607648500",
				"consultationNo": null,
				"consultationId": null,
				"activeStatus": 1,
				"oncoPatProtocolDtlList": null,
				"viewOncoPatProtocolDtlList": [
					{
						"id": 1210000057441,
						"patProtocolNo": 1210000006240,
						"itemNo": null,
						"itemName": "Herceptin",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001558,
						"routeName": "IV",
						"dose": 6,
						"doseUnitNo": 1200000001409,
						"doseUnitName": "mg/kg",
						"totalDose": null,
						"givenDose": null,
						"duration": "1",
						"administration": "In 350 ml NS",
						"infusion": "Over 60-90 min",
						"orderBy": 5,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					},
					{
						"id": 1210000057442,
						"patProtocolNo": 1210000006240,
						"itemNo": null,
						"itemName": "Docetaxel",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001558,
						"routeName": "IV",
						"dose": 75,
						"doseUnitNo": 1200000001408,
						"doseUnitName": "mg/m2",
						"totalDose": null,
						"givenDose": null,
						"duration": "1",
						"administration": "In 350 ml NS",
						"infusion": "Over 60-90 min",
						"orderBy": 6,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					},
					{
						"id": 1210000057443,
						"patProtocolNo": 1210000006240,
						"itemNo": null,
						"itemName": "Carboplatin",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001558,
						"routeName": "IV",
						"dose": 6,
						"doseUnitNo": 1200000001407,
						"doseUnitName": "AUC",
						"totalDose": null,
						"givenDose": null,
						"duration": "1",
						"administration": "In 450 ml 5%DA",
						"infusion": "Over 60-90 min",
						"orderBy": 7,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					},
					{
						"id": 1210000057444,
						"patProtocolNo": 1210000006240,
						"itemNo": null,
						"itemName": "Peg-Filgrastim",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001559,
						"routeName": "SC",
						"dose": 6,
						"doseUnitNo": 1200000001406,
						"doseUnitName": "N/A",
						"totalDose": null,
						"givenDose": null,
						"duration": "2",
						"administration": "NA",
						"infusion": "NA",
						"orderBy": 8,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					}
				]
			},
			{
				"id": 1210000006239,
				"protocolNo": 1200000003293,
				"patProtocolName": "Single Vinorelbine weekly",
				"shortName": "BrAdNq1w",
				"diagnosisNo": null,
				"diagnosisVal": "Breast- Recurrent/Metastatic Preferred Single Agents  in HER2-Negative",
				"toxicity": "Vinoralbine-- Alopecia+ GI Toxicity+ Neurotoxicity +",
				"cycleDays": 7,
				"totalCycle": 7,
				"comments": "Day 1: Vinorelbine 25mg/m2 IV- Repeat cycle weekly",
				"note": null,
				"referenceFrom": "9. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001; 92(9):2267–2272.",
				"finalizeFlag": 1,
				"startingDate": 1617008845000,
				"status": null,
				"doctorNo": 3248,
				"regNo": 1170000100717,
				"hospitalId": "11607648500",
				"consultationNo": null,
				"consultationId": null,
				"activeStatus": 1,
				"oncoPatProtocolDtlList": null,
				"viewOncoPatProtocolDtlList": [
					{
						"id": 1210000057435,
						"patProtocolNo": 1210000006239,
						"itemNo": null,
						"itemName": "GCSF",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001559,
						"routeName": "SC",
						"dose": 5,
						"doseUnitNo": 1200000001409,
						"doseUnitName": "mg/kg",
						"totalDose": 335.0,
						"givenDose": null,
						"duration": "2",
						"administration": "NA",
						"infusion": "NA",
						"orderBy": 7,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					},
					{
						"id": 1210000057431,
						"patProtocolNo": 1210000006239,
						"itemNo": null,
						"itemName": "Vinorelbine",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001558,
						"routeName": "IV",
						"dose": 25,
						"doseUnitNo": 1200000001408,
						"doseUnitName": "mg/m2",
						"totalDose": 7.75,
						"givenDose": null,
						"duration": "1",
						"administration": "In 100ml NS",
						"infusion": "Over 10 min",
						"orderBy": 3,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					}
				]
			},
			{
				"id": 1210000006243,
				"protocolNo": 1200000003297,
				"patProtocolName": "Abiraterone acetate + Prednisone  in Visceral Mets",
				"shortName": "PrPAbi",
				"diagnosisNo": null,
				"diagnosisVal": "Prostate- Castration-Recurrent\nFirst-Line Therapy WITH Visceral Metastases",
				"toxicity": null,
				"cycleDays": 30,
				"totalCycle": 7,
				"comments": "Abiraterone 1,000mg orally once daily on an empty stomach, plus prednisone 5mg orally twice daily.",
				"note": null,
				"referenceFrom": "5. Zytiga [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2017. 6. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. 7. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992. 8. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–1217.",
				"finalizeFlag": 1,
				"startingDate": 1620530151000,
				"status": null,
				"doctorNo": 3248,
				"regNo": 1170000100717,
				"hospitalId": "11607648500",
				"consultationNo": null,
				"consultationId": null,
				"activeStatus": 1,
				"oncoPatProtocolDtlList": null,
				"viewOncoPatProtocolDtlList": [
					{
						"id": 1210000057472,
						"patProtocolNo": 1210000006243,
						"itemNo": null,
						"itemName": "Abiraterone",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001554,
						"routeName": "Oral",
						"dose": 1000,
						"doseUnitNo": 1200000001406,
						"doseUnitName": "N/A",
						"totalDose": null,
						"givenDose": null,
						"duration": "1,30",
						"administration": "Daily on an empty stomach",
						"infusion": "NA",
						"orderBy": 0,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					},
					{
						"id": 1210000057473,
						"patProtocolNo": 1210000006243,
						"itemNo": null,
						"itemName": "Cortan",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001554,
						"routeName": "Oral",
						"dose": 5,
						"doseUnitNo": 1200000001406,
						"doseUnitName": "N/A",
						"totalDose": null,
						"givenDose": null,
						"duration": "1,30",
						"administration": "1+0+1, after meal",
						"infusion": "NA",
						"orderBy": 1,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					}
				]
			},
			{
				"id": 1210000006244,
				"protocolNo": 1200000003296,
				"patProtocolName": "Enzalutamide in Visceral Mets",
				"shortName": "PrPEnz",
				"diagnosisNo": null,
				"diagnosisVal": "Prostate- Castration-Recurrent\nFirst-Line Therapy WITH Visceral Metastases",
				"toxicity": null,
				"cycleDays": 30,
				"totalCycle": 7,
				"comments": "160mg (four 40mg capsules) orally daily with or without food; prednisone can be given concurrently but is not required.",
				"note": null,
				"referenceFrom": "Xtandi [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; 2016/ Beer TM, Armstrong AJ, Rathkopf DE, et al; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433",
				"finalizeFlag": 1,
				"startingDate": 1620530192000,
				"status": null,
				"doctorNo": 3248,
				"regNo": 1170000100717,
				"hospitalId": "11607648500",
				"consultationNo": null,
				"consultationId": null,
				"activeStatus": 1,
				"oncoPatProtocolDtlList": null,
				"viewOncoPatProtocolDtlList": [
					{
						"id": 1210000057475,
						"patProtocolNo": 1210000006244,
						"itemNo": null,
						"itemName": "Cortan",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001554,
						"routeName": "Oral",
						"dose": 5,
						"doseUnitNo": 1200000001406,
						"doseUnitName": "N/A",
						"totalDose": null,
						"givenDose": null,
						"duration": "1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30",
						"administration": "1+0+1, after meal",
						"infusion": "NA",
						"orderBy": 0,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					},
					{
						"id": 1210000057474,
						"patProtocolNo": 1210000006244,
						"itemNo": null,
						"itemName": "Enzalutamide",
						"medTypeNo": 1200000001403,
						"medTypeNAME": "Drug",
						"medTypeOrderBy": 3,
						"routeNo": 1200000001554,
						"routeName": "Oral",
						"dose": 160,
						"doseUnitNo": 1200000001406,
						"doseUnitName": "N/A",
						"totalDose": null,
						"givenDose": null,
						"duration": "1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30",
						"administration": "Daily with or without food",
						"infusion": "NA",
						"orderBy": 1,
						"activeStatus": 1,
						"form": null,
						"strength": null,
						"toDayGivenDose": null,
						"drugNoList": null
					}
				]
			}
		]
	}
